Alta Partners
Alta Partners is a healthcare-focused venture capital firm founded in 1996 with offices in San Francisco and Denver. The firm concentrates on early-stage investments in curative therapeutics and technology-enabled healthcare services and operates a family of NextGen funds to partner with entrepreneurs building novel biotherapeutics and healthcare delivery solutions. Alta highlights a focused portfolio approach and active operational support for portfolio companies.
Industries
Nr. of Employees
small (1-50)
Alta Partners
Jackson, Mississippi, United States, North America
Portfolio
Developing lirentelimab (AK002), an anti–Siglec-8 antibody; multiple Phase 1/2/3 programs and public offering activity documented in Alta content.
#Biopharma / Allergic and inflammatory diseases
Provider of mobile and virtual healthcare delivering in-home urgent care and hospital-at-home services; cited as an initial NextGen Fund I investment.
#Healthcare / Mobile and home-based acute care
Uses gene-editing to address xenotransplantation barriers (PERV inactivation reported); listed as an initial NextGen Fund I investment.
#Life sciences / Xenotransplantation and gene editing
Platform focused on immune programming for infectious disease; listed among Alta initial NextGen investments and timeline.
#Biopharma / Infectious disease
Develops engineered B cells as medicines; Alta participated in the Series A and subsequent financing coverage on Alta site.
#Biopharma / Engineered B-cell medicines
Listed in Alta timeline and NextGen Fund III portfolio; referenced in Alta timeline (IPO completed).
#Biopharma
Developing lirentelimab (AK002), an anti–Siglec-8 antibody; multiple Phase 1/2/3 programs and public offering activity documented in Alta content.
#Biopharma / Allergic and inflammatory diseases
Provider of mobile and virtual healthcare delivering in-home urgent care and hospital-at-home services; cited as an initial NextGen Fund I investment.
#Healthcare / Mobile and home-based acute care
Uses gene-editing to address xenotransplantation barriers (PERV inactivation reported); listed as an initial NextGen Fund I investment.
#Life sciences / Xenotransplantation and gene editing
Platform focused on immune programming for infectious disease; listed among Alta initial NextGen investments and timeline.
#Biopharma / Infectious disease
Develops engineered B cells as medicines; Alta participated in the Series A and subsequent financing coverage on Alta site.
#Biopharma / Engineered B-cell medicines
Listed in Alta timeline and NextGen Fund III portfolio; referenced in Alta timeline (IPO completed).
#Biopharma